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Data from genotyping revealed 
the presence of two promoter 
polymorphisms, c.-41_-40dupTA 
and c.-3279T>G, in both groups 
(GS patients and controls) with 
significant different allelic and, 
consequently, diplotype 
distribution (table 1).  
4. CONCLUSIONS 
      
• Bilirubin levels are mainly determined by the presence of the TA duplication in the repetitive TATA-box 
sequence of the gene promoter; 
 
• The other promoter polymorphism, c.-3279T>G, is an additional factor for the development of 
hyperbilirubinemia; 
 
• The presence of variants in the coding region of the gene seems to be associated with increased bilirubin 
levels and, therefore, associated with GS; 
 
• We describe, for the first time, seven new variants in the coding region of the gene, expanding the spectrum 
of known UGT1A1 variants.  
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2. MATERIAL AND METHODS  
 
Subjects 
 
This study included 45 GS Caucasian patients 
(36 males and 9 females, of the 
gastroenterology department of Vila Nova de 
Gaia/Espinho Hospital Center, EPE, with 
clinical diagnosis of GS, based on standard 
criteria [3]. Hyperbilirubinemia was defined for 
concentrations of total bilirubin levels (TBL) 
above 17.1 µmol/L. Data from GS patients were 
obtained from medical records. At the time of 
study they all presented normal physical 
examination, liver function tests and blood cell 
counts. Healthy control participants (n=161; 45 
males and 116 females; were included in this 
work. All participants, GS patients and healthy 
controls, gave their informed consent to 
participate in this study. 
 
Assays  
  
Blood samples of controls were collected in 
the morning after 8 hours of fasting in order to 
obtain plasma and buffy coat for DNA 
extraction. TBL concentration was determined 
by using a colorimetric method. Genomic DNA 
was extracted from blood samples using 
standard salting out method. All patients and 
controls were screened for the presence of the 
TA insertion in the TATA box region of UGT1A1 
gene by PCR amplification, with the 
introduction of a fluorochrome label (NED™) 
in the reverse primer as previously described 
[1] and the length of fragments were 
determined by capillary electrophoresis. Direct 
sequencing of the five exons, and the c.-3576 
to c.-3209 region of UGT1A1 gene was done in 
independent sequencing reactions, using the 
respective forward and reverse primers, and 
by the Dye Terminator Cycle Sequencing Kit 
(Perkin Elmer, Boston, USA) [1].  
 
Bioinformatics Tools and Data Analysis 
 
The potential pathogenicity of the new 
variants and the correspondent altered 
sequences were analyzed by 5 web available 
tools: Polyphen-2, SIFT, A-GVGD, Grantham 
Distance and BLOSUM62. 
For statistical analysis appropriate tests were 
applied using Statistical Package for Social 
Sciences (version 18, SPSS Inc., Chicago, 
USA).  
 
1. INTRODUTION 
 
 
   
3. RESULTS 
 
Table 1. Diplotypes frequencies of the two promoter UGT1A1polymorphisms 
and total bilirubin levels (TBL) in GS patients and in controls. 
Fig. 1 -  Representation of UGT1A1 
gene and UGT1A1 protein (adapted 
from Servedio et al.  2005). Arrows 
indicate the position of the altered 
residue in the new identified variants. 
Variants p.V225G and p.G308E were 
already described [4,5] . 
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The Gilbert syndrome (GS) is a benign form of 
unconjugated hyperbilirubinemia, mainly 
associated with variants in UTGT1A1 gene [1]. 
In Caucasians, behind the most common 
genetic polymorphirsm, the seven repeat 
observed at the promoter A(TA)nTAA motif, 
another polymorphism a T>G transition at 
position -3279, at the phenobarbital responsive 
enhancer module, has also been associated 
with GS [2]. The aim of this study was the 
analysis of the impact of both promoter and/or 
coding region of UGT1A1 variants on bilirubin 
levels, in GS patients and in healthy controls. 
Additionally, bioinformatics tools were used to 
study the new identified variants in order to 
evaluate their clinical significance.  
 
Table 2. Coding region variants and bilirubin levels in GS patients and controls. 
The annotation of the mutations was done according to the recommendation of the HGVS. TBL: total bilirubin levels. * Scores are 
given empirically, taken in account the number of algorithms in agreement. 
TBL: total bilirubin levels that are presented as mean ± standard deviation (SD); a p-value for 
difference in total bilirubin levels between the several diplotypes; b Multiple comparison analysis 
reveals that only [TA]7/[TA]7-G/G TBL were significant different from  other diplotypes.  
 
 
Samples 
 
TBL  
(µmol/L) 
 
cDNA  
variation 
 
Effect 
on protein  
 
Functional 
Prediction(Score)* 
 
Polymorphism 
c.-41_-40dupTA 
 
Polymorphism 
c.-3279T>G 
 
 References 
 
Patients 
1/GS 
 
29.4 
 
c.538G>C 
 
p.E180Q 
 
Tolerated (4) 
 
[TA]7/[TA]7 
 
T/G 
 
This study 
2/GS 27.7 c.674T>G p.V225G Deleterious (3) [TA]6/[TA]7 T/G [4] 
3/GS 50.1 c.674T>G p.V225G Deleterious (4) [TA]7/[TA]7 G/G [4] 
4/GS 54.2 c.923G>A p.G308E Deleterious (4) [TA]6/[TA]7 G/G [5] 
5/GS 36.6 c.1211T>C p.M404T Deleterious (4) [TA]7/[TA]7 G/G This study 
6/GS 51.3 c.1423C>T p.R475C Deleterious (4) [TA]6/[TA]7 G/G This study 
 
Controls 
1/C 
 
5.1 
 
c.643A>G 
 
p.I215V 
 
Tolerated (5) 
 
[TA]6/[TA]7 
 
T/G 
 
This study 
2/C 10.1 c.814A>G p.M272V Tolerated (4) [TA]7/[TA]7 G/G This study 
3/C 4.3 c.1156G>A p.V386I Tolerated (4) [TA]6/[TA]6 T/T This study 
4/C 5.8 c.1475T>C p.I492T Deleterious (3) [TA]6/[TA]7 T/G This study 
 
 
COOH NH2 
p.M272V 
:::::::: :::::::: 3 :::::::: :::::::: 2 4 5 1 
UDP-gluc acid Binding Domain 
 
PS  
p.E180Q 
Carboxy-Terminal Domain  
Aglycone Binding Domain 
p.M404T p.I492T p.I215V 
DT  
p.V225G p.G308E 
p.V386I p.V386I 
 
 
Diplotypes 
c.-41_-40dupTA / 
c.-3279T>G 
 
GS Patients 
 
Controls 
 
 
% (n) 
 
 
TBL  
(µmol/L) 
   
% (n) 
 
 
TBL  
(µmol/L) 
 
      p* 
[TA]6 / [TA]6 -TT  0% (0) - 33.5% (54)  7.7 ± 3.1  <0.0001 
[TA]6 / TA]6 -TG  0% (0) - 11.2% (18)  6.9 ± 3.4  
[TA]6 / [TA]7-TG 8.9% (4) 27.8 ± 7.4 32.9% (53)  9.6 ± 4.9  
[TA]7 / [TA]7-TG 4.4% (2) 29.1 ± 0.5 0% (0) -  
[TA]6 / [TA]6-GG 0% (0) - 1.9% (3)  8.4 ± 3.8  
[TA]6 / [TA]7-GG 8.9% (4)  34.8 ± 7.6  10.6% (17)  9.5 ± 4.3  
[TA]7/ [TA]7-GG 
 
77.8% (35) 
 
 37.9 ± 13.3  
  
9.9% (16) 
 
 19.5 ± 9.9b  
 
From the nine possible diplotypes combinations, four were found in GS patients and six in controls. Sequencing 
analysis of the coding regions of the UGT1A1 gene allowed the identification of nine (Fig. 1) additional single-nucleotide 
polymorphisms (SNPs), all of them in a heterozygous state. Out of these, five were identified in GS patients and four in 
controls (table 2).  
 
Estudos posteriores, em f ixas etárias diferentes e em ambos os sexos, deverão ser realizados para determinar 
como são influenciados os níveis de bilirrubina.  
